Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

Willemijn S.M.E. Theelen(The Netherlands Cancer Institute), Dawei Chen(Shandong Tumor Hospital), Vivek Verma(The University of Texas MD Anderson Cancer Center), Brian P. Hobbs(Cleveland Clinic), Heike Peulen(Radboud University Nijmegen), Joachim G.J.V. Aerts(Erasmus MC), Idris Bahce(Amsterdam UMC Location Vrije Universiteit Amsterdam), Anna Larissa N. Niemeijer(Amsterdam UMC Location Vrije Universiteit Amsterdam), Joe Y. Chang(The University of Texas MD Anderson Cancer Center), Patricia M. de Groot(The University of Texas MD Anderson Cancer Center), Quynh-Nhu Nguyen(The University of Texas MD Anderson Cancer Center), Nathan Comeaux(The University of Texas MD Anderson Cancer Center), George R. Simon(The University of Texas MD Anderson Cancer Center), Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Kewen He(The University of Texas MD Anderson Cancer Center), Roshal R. Patel(The University of Texas MD Anderson Cancer Center), John V. Heymach(The University of Texas MD Anderson Cancer Center), Paul Baas(The Netherlands Cancer Institute), James W. Welsh(The University of Texas MD Anderson Cancer Center)
The Lancet Respiratory Medicine
October 20, 2020
Cited by 555

Abstract


Related Papers

No related papers found

Powered by citation graph analysis